Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.,The Lancet

当前位置： X-MOL 学术 › Lancet › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
The Lancet ( IF 98.4 ) Pub Date : 2018-Sep-01 , DOI: 10.1016/s1470-2045(18)30379-6
Youn H Kim ₁ , Martine Bagot ₂ , Lauren Pinter-Brown ₃ , Alain H Rook ₄ , Pierluigi Porcu ₅ , Steven M Horwitz ₆ , Sean Whittaker ₇ , Yoshiki Tokura ₈ , Maarten Vermeer ₉ , Pier Luigi Zinzani ₁₀ , Lubomir Sokol ₁₁ , Stephen Morris ₇ , Ellen J Kim ₄ , Pablo L Ortiz-Romero ₁₂ , Herbert Eradat ₁₃ , Julia Scarisbrick ₁₄ , Athanasios Tsianakas ₁₅ , Craig Elmets ₁₆ , Stephane Dalle ₁₇ , David C Fisher ₁₈ , Ahmad Halwani ₁₉ , Brian Poligone ₂₀ , John Greer ₂₁ , Maria Teresa Fierro ₂₂ , Amit Khot ₂₃ , Alison J Moskowitz ₆ , Amy Musiek ₂₄ , Andrei Shustov ₂₅ , Barbara Pro ₂₆ , Larisa J Geskin ₂₇ , Karen Dwyer ₂₈ , Junji Moriya ₂₈ , Mollie Leoni ₂₈ , Jeffrey S Humphrey ₂₈ , Stacie Hudgens ₂₉ , Dmitri O Grebennik ₂₈ , Kensei Tobinai ₃₀ , Madeleine Duvic ₃₁ ,

Affiliation

Stanford University, Stanford, CA, USA.
Hôpital Saint Louis, APHP, Inserm U976, Université Paris 7, Paris, France.
University of California Irvine, Irvine, CA, USA.
University of Pennsylvania, Philadelphia, PA, USA.
Thomas Jefferson University, Philadelphia, PA, USA.
Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Guy's and St Thomas' Hospital, London, UK.
Hamamatsu University School of Medicine, Hamamatsu, Japan.
Leiden University, Leiden, Netherlands.
Institute of Hematology "Seràgnoli", University of Bologna, Bologna, Italy.
Moffitt Cancer Center, Tampa, FL, USA.
Department of Dermatology, Institute i+12, Hospital 12 de Octubre Medical School, University Complutense, Madrid, Spain.
UCLA Medical Center, Los Angeles, CA, USA.
University Hospital Birmingham, Birmingham, UK.
University Hospital MÜnster, MÜnster, Germany.
University of Alabama, Birmingham, AL, USA.
Hospices Civils de Lyon, Claude Bernard Lyon 1 University, Lyon, France.
Dana-Farber Cancer Institute, Boston, MA, USA.
University of Utah, Salt Lake City, UT, USA.
Rochester Skin Lymphoma Center, Fairport, NY, USA.
Vanderbilt University Medical Center, Nashville, TN, USA.
University of Turin, Turin, Italy.
Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Washington University, St Louis, MO, USA.
University of Washington, Seattle, WA, USA.
Northwestern University, Chicago, IL, USA.
Columbia University Medical Center, New York, NY, USA.
Kyowa Kirin Pharmaceutical Development, Princeton, NJ, USA.
Clinical Outcome Solutions, Tucson, AZ, USA.
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Cutaneous T-cell lymphomas are rare non-Hodgkin lymphomas with substantial morbidity and mortality in advanced disease stages. We compared the efficacy of mogamulizumab, a novel monoclonal antibody directed against C-C chemokine receptor 4, with vorinostat in patients with previously treated cutaneous T-cell lymphoma.

中文翻译：

Mogamulizumab 与伏立诺他治疗既往治疗的皮肤 T 细胞淋巴瘤 (MAVORIC)：一项国际、开放标签、随机、对照 3 期试验。

皮肤 T 细胞淋巴瘤是罕见的非霍奇金淋巴瘤，在疾病晚期具有很高的发病率和死亡率。我们比较了 mogamulizumab（一种针对 CC 趋化因子受体 4 的新型单克隆抗体）与伏立诺他在既往治疗过的皮肤 T 细胞淋巴瘤患者中的疗效。

更新日期：2018-08-31

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文